Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A. Yu, Jonathan W. Riess, Isamu Okamoto et al.|Clinical Lung Cancer|2021Cited by 73
1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinibJ. De Langen, Helena A. Yu, B.C. Cho et al.|Annals of Oncology|2022Cited by 7
P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line OsimertinibB.C. Cho, Helena A. Yu, Zofia Piotrowska et al.|Journal of Thoracic Oncology|2021Cited by 3